Your browser doesn't support javascript.
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 16.437
Filtrar
1.
Res Social Adm Pharm ; 16(4): 583-586, 2020 04.
Artículo en Inglés | MEDLINE | ID: mdl-32081569

RESUMEN

The 2019-nCoV infection that is caused by a novel strain of coronavirus was first detected in China in the end of December 2019 and declared a public health emergency of international concern by the World Health Organization on January 30, 2020. Community pharmacists in one of the first areas that had confirmed cases of the viral infection, Macau, joined the collaborative force in supporting the local health emergency preparedness and response arrangements. This paper aimed to improve the understanding of community pharmacists' role in case of 2019-CoV outbreak based on the practical experiences in consultation with the recommendations made by the International Pharmaceutical Federation on the Coronavirus 2019-nCoV outbreak.


Asunto(s)
Servicios Comunitarios de Farmacia/organización & administración , Infecciones por Coronavirus/epidemiología , Infecciones por Coronavirus/prevención & control , Máscaras/provisión & distribución , Neumonía Viral/epidemiología , Neumonía Viral/prevención & control , Salud Pública , Betacoronavirus , Brotes de Enfermedades , Urgencias Médicas , Monitoreo Epidemiológico , Humanos , Higiene , Macao/epidemiología , Educación del Paciente como Asunto , Farmacéuticos
2.
Sr Care Pharm ; 35(3): 108-109, 2020 Mar 01.
Artículo en Inglés | MEDLINE | ID: mdl-32070457

RESUMEN

Older people are especially vulnerable to the impacts of natural disasters such as the fires in Australia and elsewhere around the world. Health care professionals have a duty of care under these circumstances, and among those who respond are pharmacists who contribute their expertise, energy, and dedication to help where needed.


Asunto(s)
Servicios Farmacéuticos , Farmacia , Anciano , Anciano de 80 o más Años , Australia , Humanos , Farmacéuticos
3.
Sr Care Pharm ; 35(3): 110-112, 2020 Mar 01.
Artículo en Inglés | MEDLINE | ID: mdl-32070458

RESUMEN

The U.S. health care system is becoming increasingly dependent on China for medicines because it is the dominant world supplier of the ingredients needed to make thousands of medicines distributed to hospitals, pharmacies, and military hospitals. The United States is so dependent that if China stopped supplying ingredients, pharmacy shelves would be empty within months. The Food and Drug Administration is in the unenviable position of making tradeoffs between assuring high standards that Americans have come to expect and preventing drug shortages.


Asunto(s)
Preparaciones Farmacéuticas , Farmacéuticos , China , Prestación de Atención de Salud , Humanos , Farmacias , Estados Unidos
4.
Sr Care Pharm ; 35(3): 126-135, 2020 Mar 01.
Artículo en Inglés | MEDLINE | ID: mdl-32070461

RESUMEN

OBJECTIVE: To analyze medication interventions prior to and following implementation of the Pharmacy Medication Related Falls Risk Assessment consult service in an older adult population. DESIGN: Retrospective chart review. SETTING: This study involved patients admitted to the Cincinnati Veterans Affairs Medical Center's (VAMC) Community Living Center (CLC), an institutional practice setting. PATIENTS, PARTICIPANTS: Any patient who experienced a fall while admitted to the CLC during fiscal years 2013 or 2018 was considered for inclusion. Patients were excluded if falls were not evaluated by a provider, the patient expired within 10 days after falling, or falls in fiscal year 2018 that did not have a pharmacy consult placed. Fifty falls from each fiscal year were selected. MAIN OUTCOME MEASURES: The primary endpoint encompassed the number of pharmacy medication interventions made within 10 days postfall, with a secondary endpoint evaluating subsequent falls within 30 days of initial event. RESULTS: Following consult implementation, a larger number of pharmacist recommendations (40 vs. 123) and subsequent interventions (accepted recommendations) within ten days postfall (12 vs. 49) were completed. There were 14 subsequent falls within 30 days of the initial event for both fiscal years. A larger percentage of falls and patients experiencing falls from each fiscal year did not receive previous medication interventions. CONCLUSION: Consult implementation increased the number of pharmacist recommendations and subsequent interventions for patients within ten days postfall, reducing the risk of adverse effects, drug-drug interactions, subsequent falls, and polypharmacy.


Asunto(s)
Servicios Farmacéuticos , Veteranos , Accidentes por Caídas , Anciano , Humanos , Farmacéuticos , Estudios Retrospectivos
5.
Sr Care Pharm ; 35(3): 136-144, 2020 Mar 01.
Artículo en Inglés | MEDLINE | ID: mdl-32070462

RESUMEN

OBJECTIVES: To describe and gather further details about the clinical and educational activities that were documented by the geriatric pharmacist resident during both weekly interprofessional Acute Care for the Elderly (ACE) rounds as well as bedside patient counseling. DESIGN: Retrospective chart review (quality improvement project). SETTING: Inpatient geriatric service at University of Pittsburgh Medical Center (UPMC). PATIENTS: Medical learners selected one complex patient from the geriatric service for ACE rounds each week. ACTIVITIES: The geriatric pharmacist resident provided clinical information and medication education to the interprofessional team and to the patient and/or family at their bedside. Activities were documented in a newly developed template. MAIN OUTCOME MEASURES: Patient demographics, medication categories, discrepancies and dosing changes, time-in-rounds, and team members. RESULTS: De-identified data from 18 patients (72.2% female, average age 82.5 ± 9.18 years) over a 6-month period were collected and analyzed. The geriatric pharmacist resident provided most education to the team on antibiotics, antidepressants, over-thecounters (OTCs), and prescription pain medications during ACE rounds. They provided most education to the patient/family on prescription pain medications, antidepressants, OTCs, and anticoagulants. The pharmacist resident identified 38 medication discrepancies (72.2% of patients had ≥ 1 discrepancy, range 0-7) and clinically significant drug-drug interactions in 15 patients. The pharmacist resident recommended dosing changes in 12 patients and therapeutic alternatives in 11 patients. The ACE rounds lasted on average 26.6 [± 6.42] minutes and included medicine, pharmacy, social work, nurse case management, nursing, and nutrition and rehabilitative services when necessary. CONCLUSION: The results provide insight into both the clinical and educational activities of the geriatric pharmacist resident in support of interprofessional rounds.


Asunto(s)
Educación en Farmacia , Servicios Farmacéuticos , Farmacias , Anciano , Anciano de 80 o más Años , Femenino , Humanos , Masculino , Farmacéuticos , Estudios Retrospectivos
6.
Sr Care Pharm ; 35(2): 81-84, 2020 Feb 01.
Artículo en Inglés | MEDLINE | ID: mdl-32085817

RESUMEN

An interprofessional, team-based approach has become common in a variety of settings. However, consultant pharmacist participation in home health care (HHC) has been limited. To evaluate a potential need for pharmacists in HHC, the objective of this project was to document the medication complexity of patients seen by an established HHC consultant pharmacist service. This retrospective review reports on medication regimen complexity in 79 patients receiving this service using the Patient-Level Medication Regimen Complexity Index (MRCI) tool. The average MRCI score was 30 (± 15 standard deviation), suggesting a high level of medication regimen complexity in this population. High scores have been correlated with increased potential adverse drug events, 30-day hospital readmissions, and reduced adherence. Further research is needed for both the utilization of consultant pharmacists in HHC and the use of MRCI in identifying HHC patients needing pharmacist services.


Asunto(s)
Servicios de Atención de Salud a Domicilio , Servicios Farmacéuticos , Consultores , Humanos , Farmacéuticos , Estudios Retrospectivos
7.
Sr Care Pharm ; 35(2): 75-80, 2020 Feb 01.
Artículo en Inglés | MEDLINE | ID: mdl-32019642

RESUMEN

This report describes a case of hypertensive crisis identified by two pharmacists conducting a patient home visit. A 72-year-old woman living in a rural town in Eastern Washington state was referred for a pharmacist home visit by her care coordinator, who had concerns of possible medication-related issues. The patient had a history of type 2 diabetes mellitus, hypertension, ischemic stroke, heart failure with preserved ejection fraction, hypothyroidism, and unspecified back pain. This patient also experienced additional challenges resulting from living in a rural and medically underserved community. During the home visit, the patient's chief complaint was recurrent, painful migraine headaches that she self-treated with nonsteroidal anti-inflammatory medication. Upon examination, the pharmacists found the patient's blood pressure to be 223/132 mm Hg and her self-monitoring log consistently showed blood pressure readings greater than 180/110 mm Hg with a pulse between 75 bpm to 80 bpm. The patient was referred to the emergency department after determining her blood pressure met criteria for hypertensive crisis despite her adherence to her current antihypertensive regimen. She was hospitalized for three days. After her hospitalization, she was referred to her primary care providers and her pharmacist for follow up. The pharmacist reconciled her current medication regimen and made guideline-directed adjustments to her antihypertensive medications. Six months after her hospitalization her blood pressure was within goal and associated headaches had resolved.


Asunto(s)
Diabetes Mellitus Tipo 2 , Visita Domiciliaria , Anciano , Antihipertensivos , Femenino , Humanos , Farmacéuticos , Washingtón
8.
Sr Care Pharm ; 35(2): 93-106, 2020 Feb 01.
Artículo en Inglés | MEDLINE | ID: mdl-32019644

RESUMEN

OBJECTIVE: To identify key beliefs that influence behavior, regarding Medicare's Annual Wellness Visit (AWV) and older patients' willingness to implement personalized prevention plans.
DESIGN: Cross-sectional. In-depth semi-structured focus group sessions with Medicare patients in July 2018.
SETTING: Two primary care physician-based practices.
INTERVENTION: A trained moderator facilitated two focus group sessions, and used open-ended questions based on the theory of planned behavior to elicit behavioral, normative, and control beliefs associated with implementing personalized prevention plans.
MAIN OUTCOME MEASURE: Content analysis of the focus groups' transcribed data was used to identify modal salient beliefs. Transcribed focus group sessions were analyzed utilizing grounded-theory methods for emergent themes.
RESULTS: A total of 13 older patients participated in the focus group sessions. Prevalent behavioral beliefs among participants influenced by patient-centered care outcomes included improvement in physical activity, adopting a healthy balanced diet, and weight loss.
Interpersonal and environmental disparities influenced commonly reported control factors such as lack of support at home and affordable fitness facilities. Macro-level influences such as physicians and social marketing by insurance providers, and health partners and spousal support were identified as important normative factors.
CONCLUSION: Identified salient beliefs were congruent to social determinants of health in Medicare patients. Results of the study demonstrate perceived enablers and barriers of elderly patients regarding implementing health-promoting advice. AWV pharmacists should address perceived barriers to improve attitudes and self-efficacy; and incorporate enabling beliefs into adherence strategies to improve adoption of health recommendations.


Asunto(s)
Medicare , Farmacéuticos , Anciano , Estudios Transversales , Ejercicio , Grupos Focales , Humanos , Estados Unidos
9.
Am J Health Syst Pharm ; 77(4): 254-258, 2020 02 07.
Artículo en Inglés | MEDLINE | ID: mdl-31907520
10.
J Surg Res ; 246: 482-489, 2020 02.
Artículo en Inglés | MEDLINE | ID: mdl-31635833

RESUMEN

The Joint Commission has established medication reconciliation as a National Patient Safety Goal, but it has not been studied much in trauma even though it is integral to safe patient care. This article reviews the existing medication reconciliation strategies and their applicability to the trauma setting. To perform medication reconciliation, hospitals use a variety of strategies including pharmacists or pharmacy technicians, electronic medical record tools, and patient-centered strategies. All of these strategies are limited in trauma. Subpopulations such as injured children, the elderly, and those with brain trauma are particularly challenging and are at risk for suboptimal care from inaccurate medication reconciliation. Further research is necessary to create a safe and efficient system for trauma patients.


Asunto(s)
Conciliación de Medicamentos/organización & administración , Seguridad del Paciente , Centros Traumatológicos/organización & administración , Heridas y Traumatismos/terapia , Factores de Edad , Anciano , Niño , Registros Electrónicos de Salud/organización & administración , Humanos , Atención Dirigida al Paciente/organización & administración , Farmacéuticos/organización & administración , Técnicos de Farmacia/organización & administración , Rol Profesional , Estados Unidos
11.
Int J Clin Pharmacol Ther ; 58(2): 82-88, 2020 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-31724529

RESUMEN

OBJECTIVE: The main objective of this study was to evaluate therapeutic drug monitoring (TDM) services for antibiotics and investigate the association between non-adherence to TDM guidelines and development of nephrotoxicity. MATERIALS AND METHODS: This retrospective study was conducted using electronic health records of hospitalized patients who received antibiotics for which TDM was requested over a 1-year period. Adherence to TDM guidelines was measured by reviewing appropriate indications, sampling times, result reporting, and clinical pharmacist interventions. RESULTS: A total of 1,179 patients (65% males), for whom TDM was requested during 2017 were included. Upon an assessment of the appropriateness of sampling times, we found that ~ 15% of samples were drawn at the wrong time, and in over 46% of the cases, TDM service was inconsistent with guidelines. Further, although physicians accepted the majority of pharmacists' interventions related to the TDM service, the pharmacist did not provide any recommendation in more than one-third of the cases. Nephrotoxicity was the most common adverse reaction and was observed in 19.5% of the patients. Furthermore, we found a significant correlation between nephrotoxicity and non-adherence to TDM guidelines (OR = 1.47; p = 0.014). Our study shows that adherence to the guidelines and implementation of an appropriate and effective TDM service for antibiotics increases the number of patients with adequate plasma levels, optimizes clinical outcomes, and minimizes toxicities. Moreover, there was a strong association between non-adherence to the TDM guidelines and development of nephrotoxicity. CONCLUSION: The findings suggest that adherence to TDM guidelines not only improves clinical practice but also contributes to the reduction of the cost associated with the development of nephrotoxicity.


Asunto(s)
Antibacterianos/uso terapéutico , Monitoreo de Drogas , Adhesión a Directriz/estadística & datos numéricos , Insuficiencia Renal/prevención & control , Antibacterianos/efectos adversos , Registros Electrónicos de Salud , Femenino , Humanos , Masculino , Farmacéuticos , Insuficiencia Renal/inducido químicamente , Estudios Retrospectivos
12.
Oral Dis ; 26(1): 89-95, 2020 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-31596995

RESUMEN

OBJECTIVES: To investigate the clinical advices pharmacists would give to patients who present with various oral mucosal lesions. SUBJECTS AND METHODS: One hundred and twenty pharmacists in three major cities in the United Arab Emirates (UAE) were approached by senior dental students acting as mystery shoppers. Pharmacists were shown an image of one of four oral mucosal lesions representing candidosis, aphthous ulcer, erosive lichen planus and squamous cell carcinoma (SCC). Pharmacists' referral pattern and choices of medications were recorded and assessed against demographic variables. RESULTS: Eighty-eight per cent (88%) of pharmacists dispensed a non-prescription medication to treat the oral lesions, including SCC, while only 12% recommended that the lesion shown to them be assessed by a clinician. Among all referral recommendations, 32% were for SCC (p = .006). Geographical proximity of a clinic to the pharmacy was a significant factor in determining pharmacists' referral recommendation (p = .036). CONCLUSION: Most pharmacists dispensed a medication for oral mucosal lesions, including potentially malignant and malignant ones, without referring patients to a medical or dental practitioner. Pharmacists should be aware of the serious nature of some oral mucosal lesions and the necessity to refer those cases to a qualified practitioner for proper clinical assessment.


Asunto(s)
Competencia Clínica , Servicios Comunitarios de Farmacia , Enfermedades de la Boca/diagnóstico , Enfermedades de la Boca/terapia , Candidiasis/diagnóstico , Candidiasis/terapia , Carcinoma de Células Escamosas/diagnóstico , Carcinoma de Células Escamosas/terapia , Humanos , Liquen Plano/diagnóstico , Liquen Plano/terapia , Mucosa Bucal/patología , Farmacéuticos , Derivación y Consulta/estadística & datos numéricos , Estomatitis Aftosa/diagnóstico , Estomatitis Aftosa/terapia , Emiratos Árabes Unidos
15.
J Oncol Pharm Pract ; 26(1): 13-22, 2020 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-30832554

RESUMEN

PURPOSE: To describe the outcomes of a pharmacist-led multi-center, collaborative patient education and proactive adverse event management program in a community-based oncology setting. METHODS: Patients with EGFR mutation-positive (EGFRm+) non-small cell lung cancer, newly prescribed with oral afatinib, and monitored as part of the Florida Cancer Specialists patient management program, were included in a retrospective, observational analysis. During follow-up, data were collected on adverse event frequency, and changes in afatinib dosing. Data analyses were descriptive and exploratory in nature. RESULTS: The mean age of the 123 patients included in the analysis was 69 years, and 78% were female. At the time of the analysis, 3 patients had discontinued before receiving treatment, 89 patients had discontinued afatinib treatment, and 31 patients were continuing to receive afatinib treatment. The most common afatinib-related adverse events were diarrhea (85%), rash/skin reactions (58%), stomatitis/mucositis (19%), and paronychia (16%). Overall, 13% of patients discontinued due to afatinib-related adverse events. The median duration of treatment was 4 months in patients who discontinued due to adverse events, 6 months in those who discontinued for other reasons, and 18 months in those who were continuing to receive therapy. Afatinib dose-reductions were more frequent in patients continuing treatment versus those who discontinued due to adverse events (77% vs. 42%, respectively). CONCLUSIONS: Findings suggest that adverse events in patients with EGFRm + non-small cell lung cancer receiving afatinib can be successfully managed in a community-based, real-world setting with the help of collaborative pharmacist-led patient education, adverse event monitoring, and continuous support.


Asunto(s)
Afatinib/efectos adversos , Antineoplásicos/efectos adversos , Carcinoma de Pulmón de Células no Pequeñas/tratamiento farmacológico , Neoplasias Pulmonares/tratamiento farmacológico , Educación del Paciente como Asunto/tendencias , Farmacéuticos/tendencias , Adulto , Anciano , Anciano de 80 o más Años , Carcinoma de Pulmón de Células no Pequeñas/diagnóstico , Carcinoma de Pulmón de Células no Pequeñas/genética , Servicios Comunitarios de Farmacia/tendencias , Efectos Colaterales y Reacciones Adversas Relacionados con Medicamentos/diagnóstico , Efectos Colaterales y Reacciones Adversas Relacionados con Medicamentos/terapia , Receptores ErbB/genética , Femenino , Humanos , Neoplasias Pulmonares/diagnóstico , Neoplasias Pulmonares/genética , Masculino , Persona de Mediana Edad , Educación del Paciente como Asunto/métodos , Relaciones Profesional-Paciente , Estudios Retrospectivos
16.
J Oncol Pharm Pract ; 26(1): 29-35, 2020 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-30832556

RESUMEN

OBJECTIVES: This study aimed to investigate the effectiveness of pharmacist intervention in reducing and preventing prescribing errors of investigational drugs for cancer patients. MATERIALS AND METHODS: A retrospective study was conducted during two periods: a baseline period from December 2015 to June 2016 and an intervention period from July 2016 to February 2017. The investigational drug service (IDS) pharmacists performed active interventions during the intervention period. RESULTS: Among 12,387 investigational drug orders, 395 (6.1%) prescribing errors were detected in 6477 orders at the baseline period, and 278 errors (4.7%) were detected in 5,910 orders at the intervention period. To identify factors that affect prescribing errors, three models were constructed for the multivariate analysis. Among factors affecting prescribing errors, sponsor initiated trial (SIT) was the strongest factor (AOR: 4.16, 95% CI: 3.31-5.23). Pharmacist intervention reduced prescribing errors by at least 25% in all constructed models after adjusting for confounding variables. Prescribing errors were 1.3 times higher when dealing with intravenous medications than when dealing with oral medications. There were 60% fewer prescribing errors in the blinded study than in the open study. SIT and multi-center/multi-nation studies had 4.2 and 2.4 times more frequent prescribing errors than in investigator-initiated trials (IIT) and single-center/single-nation studies, respectively. Fewer errors occurred in phase 2 and trials covering both phase 1 and phase 2 (phase 1/2) than in phase 3 trials. CONCLUSIONS: The IDS pharmacist intervention in cancer clinical trials was associated with significant reductions in prescribing errors and may lead to increased medication safety.


Asunto(s)
Drogas en Investigación/efectos adversos , Errores de Medicación/prevención & control , Neoplasias/tratamiento farmacológico , Farmacéuticos , Servicio de Farmacia en Hospital/métodos , Rol Profesional , Femenino , Humanos , Masculino , Neoplasias/epidemiología , Farmacéuticos/tendencias , Servicio de Farmacia en Hospital/tendencias , República de Corea/epidemiología , Estudios Retrospectivos
17.
J Oncol Pharm Pract ; 26(1): 116-123, 2020 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-31096855

RESUMEN

PURPOSE: Nurse practitioners, physician assistants, and pharmacists are advanced practice providers who are highly trained and qualified healthcare professionals that can help support traditional demands on oncologists' increased time in direct patient care. The purpose of this study was to detail and assess the creation of a privileging process for this group of medical professionals within an academic medical center. Obtaining the designation of limited oncology practice provider (LOPP) gives the right to modify chemotherapy orders and to order supportive care medications. METHODS: An interdisciplinary team developed a comprehensive training process inclusive of required educational domains, knowledge goals, and educational activities to become an LOPP. In 2018, five years after the implementation of the privileging process, a survey was distributed to assess perceptions of the training process and integration of LOPPs within oncology practice. RESULTS: Most oncologists noted that working with LOPPs is beneficial to oncology practice (94%) and that they make modifying chemotherapy orders more efficient (87%). Greater than 82% of LOPPs also reported that their privileges streamline the chemotherapy process and make them feel valuable. CONCLUSION: The creation of the LOPP designation is an effective way to integrate nurse practitioners, physician assistants, and pharmacists within oncology practice. The inclusion of a focused privileging process ensures the safety of cancer care provided and has created a streamlined process for chemotherapy modifications and supportive care.


Asunto(s)
Centros Médicos Académicos/normas , Enfermería de Práctica Avanzada/normas , Oncología Médica/normas , Enfermeras Practicantes/normas , Farmacéuticos/normas , Asistentes Médicos/normas , Centros Médicos Académicos/métodos , Enfermería de Práctica Avanzada/métodos , Antineoplásicos/administración & dosificación , Femenino , Humanos , Masculino , Oncología Médica/métodos , Encuestas y Cuestionarios
18.
J Oncol Pharm Pract ; 26(1): 156-174, 2020 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-31354102

RESUMEN

The development of BCR-ABL-targeting tyrosine kinase inhibitors has transformed chronic phase chronic myeloid leukemia (CP CML) from a disease with a terminal prognosis to a treatable chronic illness. Long-term treatment with tyrosine kinase inhibitors means that patients have to be clinically managed and monitored over extended periods of time, thus a patient-centered, medically integrated, and multidisciplinary oncology healthcare team is required to support patients through their journey. Pharmacists work with patients, physicians, and the wider support team to select the optimum therapy plan for a given patient. These decisions are based on risk factors, comorbidities, concomitant medications, and personal circumstances and pharmacists advise on the efficacy and safety of different treatment options. Additionally, pharmacists are a key point-of-contact and resource for monitoring patient response to treatment, identifying and managing adverse events and drug-drug interactions, any subsequent therapy plan modifications, and, potentially, treatment-free remission. Pharmacists also assist with patient education, medication adherence, and financial discussions with patients throughout the long course of the disease. This review provides an overview of BCR-ABL tyrosine kinase inhibitors, discusses the role of the medically integrated pharmacy team, and suggests strategies that pharmacists can use in patient management and clinical decision-making to optimize the treatment of CP CML.


Asunto(s)
Antineoplásicos/uso terapéutico , Leucemia Mielógena Crónica BCR-ABL Positiva/tratamiento farmacológico , Cumplimiento de la Medicación , Farmacéuticos/tendencias , Inhibidores de Proteínas Quinasas/uso terapéutico , Interacciones de Drogas/fisiología , Humanos , Leucemia Mielógena Crónica BCR-ABL Positiva/diagnóstico , Oncología Médica/métodos , Oncología Médica/tendencias , Proteínas Tirosina Quinasas/antagonistas & inhibidores
19.
J Oncol Pharm Pract ; 26(1): 175-186, 2020 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-31554471

RESUMEN

Gender disparity exists in leadership roles within healthcare. While the majority of the healthcare workforce is comprised of women, significantly fewer women occupy leadership positions, particularly at executive and board levels. As the field of oncology pharmacy continues to rapidly expand and evolve, an assessment of the current state of women in oncology pharmacy leadership roles is vital to the growth and development of the profession. In the fall of 2017, the Hematology/Oncology Pharmacy Association (HOPA) hosted a summit to explore leadership issues facing women in oncology pharmacy which have the potential to affect our membership and our profession. This meeting included invited participants from across the fields of oncology and pharmacy and was part of HOPA's strategic leadership initiative developed through the work of the HOPA Leadership Development Committee in 2016. This promotes a primary goal of HOPA, which is to support oncology pharmacists as they assume leadership roles within their practices and within healthcare to assure oncology pharmacy is integrated into cancer care. The purpose of this white paper is to (1) summarize key issues that were identified through a membership survey; (2) review ongoing efforts to address the needs of female oncology pharmacists in leadership development; (3) serve as a call to action for individuals and professional organizations to assist with and disseminate these efforts and highlight available resources, and (4) to provide practical steps to meet the needs of individuals, training programs, and institutions/employers.


Asunto(s)
Liderazgo , Neoplasias/tratamiento farmacológico , Farmacéuticos/tendencias , Farmacia/tendencias , Sexismo/tendencias , Femenino , Humanos , Servicios Farmacéuticos/tendencias , Farmacia/métodos , Sexismo/prevención & control
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA